Exelixis (EXEL) Expected to Announce Quarterly Earnings on Tuesday

Exelixis (NASDAQ:EXEL) is projected to announce its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.75 per share and revenue of $607.4880 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 5:00 PM ET.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The business had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. During the same period in the previous year, the company earned $0.55 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, analysts expect Exelixis to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $43.68 on Friday. Exelixis has a 12 month low of $33.76 and a 12 month high of $49.62. The firm has a market capitalization of $11.10 billion, a P/E ratio of 15.77, a P/E/G ratio of 0.98 and a beta of 0.38. The company’s fifty day moving average price is $43.31 and its 200 day moving average price is $42.80.

Insider Buying and Selling

In other Exelixis news, Director Bob Oliver sold 30,250 shares of Exelixis stock in a transaction on Friday, February 13th. The shares were sold at an average price of $43.81, for a total value of $1,325,252.50. Following the transaction, the director directly owned 21,120 shares in the company, valued at approximately $925,267.20. The trade was a 58.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 67,814 shares of Exelixis stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the completion of the transaction, the executive vice president owned 381,908 shares in the company, valued at approximately $16,620,636.16. This represents a 15.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 362,849 shares of company stock valued at $15,917,463 in the last quarter. Corporate insiders own 2.82% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Invesco Ltd. increased its stake in Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock valued at $265,379,000 after purchasing an additional 94,218 shares during the period. Mercer Global Advisors Inc. ADV increased its stake in shares of Exelixis by 107.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 143,780 shares of the biotechnology company’s stock worth $6,302,000 after acquiring an additional 74,360 shares during the period. Vident Advisory LLC increased its stake in shares of Exelixis by 2.0% during the fourth quarter. Vident Advisory LLC now owns 153,901 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 3,085 shares during the period. EP Wealth Advisors LLC acquired a new position in shares of Exelixis during the fourth quarter worth about $1,003,000. Finally, Mackenzie Financial Corp increased its stake in shares of Exelixis by 13.8% during the fourth quarter. Mackenzie Financial Corp now owns 43,685 shares of the biotechnology company’s stock worth $1,920,000 after acquiring an additional 5,290 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on EXEL. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Wells Fargo & Company boosted their price target on shares of Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Wall Street Zen cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. Stifel Nicolaus boosted their price target on shares of Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Finally, Bank of America cut shares of Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price target for the company. in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $47.00.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.